Pharmacological Treatment of H. Pylori Related Peptic Ulcer Disease

Pharmacological Treatment of H. Pylori Related Peptic Ulcer Disease provides an in-depth, evidence-based exploration of the therapeutic strategies used to eradicate Helicobacter pylori (H. pylori) infection and manage its associated gastrointestinal complications. This course is designed for healthcare professionals seeking to enhance their understanding of antimicrobial regimens, acid suppression therapy, and treatment algorithms aligned with current clinical guidelines.

The course covers the pathophysiology of H. pylori-related ulcers, the mechanisms of bacterial persistence, and factors contributing to treatment resistance. Special attention is given to first-line, second-line, and salvage therapies, with detailed discussion of antibiotic combinations, dosing schedules, and strategies to address adherence and adverse effects. Consideration is also given to the management of special populations, including patients with antibiotic allergies, comorbidities, or prior treatment failure.

Topics covered include:

• Pathophysiology and Clinical Significance: Understanding the role of H. pylori in gastric and duodenal ulcer formation and related complications such as GI bleeding and gastric malignancy.
• Diagnostic Approaches: Overview of non-invasive and invasive diagnostic methods, including urea breath test, stool antigen test, endoscopy with biopsy, and histology.
• First-Line Treatment Regimens: Triple and quadruple therapies incorporating proton pump inhibitors (PPIs), clarithromycin, amoxicillin, metronidazole, and bismuth compounds.
• Resistance and Treatment Failure: Management strategies for clarithromycin- or metronidazole-resistant strains, and use of salvage therapies such as levofloxacin-based or rifabutin-containing regimens.
• Adjunctive and Supportive Therapies: Role of probiotics, dietary considerations, and management of therapy-related adverse effects.
• Follow-Up and Eradication Testing: Post-treatment testing recommendations and clinical monitoring to confirm bacterial eradication and mucosal healing.
• Special Populations and Considerations: Tailoring regimens for pediatric, elderly, and immunocompromised patients, and those with penicillin allergy.
• Case Studies and Clinical Scenarios: Application of guidelines to real-world patient cases to illustrate treatment selection and problem-solving in complex presentations.

Completion Requirements:

To receive full CE credit for this course, participants must:

• Be registered for the course.
• Review all course material.
• Complete the post-test with a passing score of 70% or higher.
• Submit the course evaluation survey.

Note: Optional tools such as treatment algorithms, dosing charts, and resistance prevalence maps may be provided for clinical reference.

Important Disclosures:

• Conflict of Interest: he planners, authors, and presenters have disclosed no conflicts of interest or financial relationships with any commercial entities related to this activity.
• Commercial Support: This CE activity is not commercially sponsored.
• Non-Endorsement: Approval of this CE course applies only to its educational content and does not imply endorsement of any specific product, service, or company.
• Off-Label Product Use: Off-label or non-FDA-approved uses of certain antibiotics may be discussed when clinically appropriate and supported by current guidelines.